Benzinga··Vandana SinghEli Lilly's Retatrutide Posts Blockbuster Weight Loss Results in Phase 3 Trial
Eli Lilly's obesity drug retatrutide achieves 28.3% average weight loss in Phase 3 trial, with 65.3% of patients reaching non-obese BMI levels.
LLYPhase 3 trialclinical trial results